2'-O-propyluridine | 160527-05-9

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 2'-O-propyluridine
• 英文别名: 1-[(2R,3R,4R,5R)-4-hydroxy-5-(hydroxymethyl)-3-propoxyoxolan-2-yl]pyrimidine-2,4-dione
• CAS: 160527-05-9
• 化学式: C₁₂H₁₈N₂O₆
• 分子量: 286.285
• InChiKey: AGCKEZUQNFXVKQ-QCNRFFRDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  108
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2'-O-propyluridine 在 吡啶 、 三甲基氯硅烷 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 生成 N₄-Benzoyl-5'-O-(dimethoxytrityl)-2'-O-propylcytidine
  参考文献：
  名称：

  [EN] EXTRAHEPATIC DELIVERY
  [FR] ADMINISTRATION EXTRA-HÉPATIQUE

  摘要：

  公开号：

  WO2021092371A3
• 作为产物：
  描述：

  C₂₈H₃₆N₂O₆Si 在 氢氟酸 、 三乙胺 作用下， 生成 2'-O-propyluridine
  参考文献：
  名称：

  [EN] EXTRAHEPATIC DELIVERY
  [FR] ADMINISTRATION EXTRA-HÉPATIQUE

  摘要：

  公开号：

  WO2021092371A3

文献信息

• Process for the preparation of 2'-O-alkyl purine phosphoramidites
  申请人：Isis Pharmceuticals, Inc.

  公开号：US05646265A1

  公开（公告）日：1997-07-08

  2'-O-alkylated guanosine, uridine, cytidine, and 2,6-diaminopurine 3'-O-phosphoramidites are prepared by alkylating nucleoside precursors, adding suitable blocking groups and phosphitylating. Alkylation is effected on 2,6-diamino-9-(.beta.-D-ribofuranosyl)purine followed by deamination to prepare guanosine 2'-O-alkylated 3'-O-phosphormidites. Alkylation is effected on a dialkyl stannylene derivative of uridine to prepare uridine 2'-O-alkylated 3'-O-phosphormidites. Alkylation is effected directly on cytidine to prepare cytidine 2'-O-alkylated 3'-O-phosphormidites. Alkylation is effected directly on 2,6-diaminopurine to prepare 2,6-diaminopurine 2'-O-alkylated 3'-O-phosphormidites.

  2'-O-烷基化鸟苷、尿苷、胞苷和2,6-二氨基嘌呤3'-O-磷酰胺酯是通过烷基化核苷前体、添加适当的阻断基团和磷酰化来制备的。烷基化是在2,6-二氨基-9-(β-D-核糖呋喃基)嘌呤上进行的，随后进行去氨基化以制备鸟苷2'-O-烷基化3'-O-磷酰胺酯。烷基化是在尿苷的二烷基基锡衍生物上进行的，以制备尿苷2'-O-烷基化3'-O-磷酰胺酯。烷基化是直接在胞苷上进行的，以制备胞苷2'-O-烷基化3'-O-磷酰胺酯。烷基化是直接在2,6-二氨基嘌呤上进行的，以制备2,6-二氨基嘌呤2'-O-烷基化3'-O-磷酰胺酯。
• Sugar modified oligonucleotides
  申请人：ISIS Pharmaceuticals, Inc.

  公开号：US20030004325A1

  公开（公告）日：2003-01-02

  Compositions and methods are provided for the treatment and diagnosis of diseases amenable to modulation of the production of selected proteins. In accordance with preferred embodiments, oligonucleotides and oligonucleotide analogs are provided which are specifically hybridizable with a selected sequence of RNA or DNA wherein at least one of the 2′-deoxyfuranosyl moieties of the nucleoside unit is modified. Treatment of diseases caused by various viruses and other causative agents is provided.

  提供了用于治疗和诊断可通过调节特定蛋白质产生的疾病的组合物和方法。根据优选实施例，提供了可以与RNA或DNA的选定序列特异性杂交的寡核苷酸和寡核苷酸类似物，其中核苷酸单元的至少一个2'-脱氧呋喃糖苷基被修改。提供了治疗由各种病毒和其他致病因素引起的疾病的方法。
• 2' -modified oligonucleotides
  申请人：ISIS Pharmaceuticals, Inc.

  公开号：US20030187240A1

  公开（公告）日：2003-10-02

  Compositions and methods are provided for the treatment and diagnosis of diseases amenable to modulation of the production of selected proteins. In accordance with preferred embodiments, oligonucleotides and oligonucleotide analogs are provided which are specifically hybridizable with a selected sequence of RNA or DNA wherein at least one of the 2′-deoxyfuranosyl moieties of the nucleoside unit is modified. Treatment of diseases caused by various viruses and other causative agents is provided.

  提供了用于治疗和诊断可调节选择蛋白质生成的疾病的组合物和方法。根据优选实施例，提供了可以与RNA或DNA的选择序列特异性杂交的寡核苷酸和寡核苷酸类似物，其中核苷酸单元的至少一个2'-脱氧呋喃糖基团被修饰。提供了治疗由各种病毒和其他致病因子引起的疾病的方法。
• 2'-MODIFIED OLIGONUCLEOTIDES
  申请人：Cook Dan Phillip

  公开号：US20080032945A1

  公开（公告）日：2008-02-07

  Compositions and methods are provided for the treatment and diagnosis of diseases amenable to modulation of the production of selected proteins. In accordance with preferred embodiments, oligonucleotides and oligonucleotide analogs are provided which are specifically hybridizable with a selected sequence of RNA or DNA wherein at least one of the 2′-deoxyfuranosyl moieties of the nucleoside unit is modified. Treatment of diseases caused by various viruses and other causative agents is provided.

  本发明提供了用于治疗和诊断对调节所选蛋白质产生敏感的疾病的组合物和方法。根据优选实施例，提供了可以与RNA或DNA的所选序列特异性杂交的寡核苷酸和寡核苷酸类似物，其中核苷酸单元的至少一个2'-脱氧呋喃糖基团被修改。提供了治疗由各种病毒和其他致病因子引起的疾病的方法。
• Process for the preparation of 2′-O-alkyl-guanosine, cytidine, and uridine phosphoramidites
  申请人：ISIS Pharmaceuticals, Inc.

  公开号：US06242592B1

  公开（公告）日：2001-06-05

  Processes for preparing 2′-O-alkylated guanosine, uridine, cytidine, and 2,6-diaminopurine 3′-O-phosphoramidites include the steps of alkylating nucleoside precursors, adding suitable blocking groups and phosphitylating. For the guanosine 2′-O-alkylated 3′-O-phosphoramidites, alkylation is effected on 2,6-diamino-9-(&bgr;-D-ribofuranosyl) purine followed by deamination. For uridine 2′-O-alkylated 3′-O-phosphoramidites, alkylation is effect on a dialkyl stannylene derivative of uridine. For cytidine 2′-O-alkylated 3′-O-phosphoramidites, alkylation is effected directly on cytidine. Alkylation is effected directly upon 2,6-diaminopurine.

  制备2'-O-烷基化鸟苷、尿苷、胞苷和2,6-二氨基嘌呤3'-O-磷酰胺酯的过程包括烷基化核苷前体、添加适当的阻断基和磷酰化步骤。对于鸟苷2'-O-烷基化3'-O-磷酰胺酯，烷基化作用在2,6-二氨基-9-(&bgr;-D-核糖)嘌呤上，然后进行去氨作用。对于尿苷2'-O-烷基化3'-O-磷酰胺酯，烷基化作用在尿苷的二烷基锡衍生物上。对于胞苷2'-O-烷基化3'-O-磷酰胺酯，烷基化作用直接在胞苷上。烷基化作用直接作用在2,6-二氨基嘌呤上。